ArticleScientific reports2025
Polygenic risk scores of rheumatoid arthritis associated with seropositivity and bone erosions in a Taiwanese population.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Polygenic risk scores (PRS) are widely used to estimate disease risks and predict clinical outcomes. However, ethnic differences exist worldwide. We aimed to use PRS for predicting the development of rheumatoid arthritis (RA) in a Taiwanese population and investigate whether PRS of RA may be associated with structural damage. PRS was calculated via GWAS data from 2,042 RA patients and 7,950 controls from the Taiwan Precision Medicine Initiative. LDpred2, PLINK, and PRSice-2 models were used to evaluate RA susceptibility via AUC. Clinical factors, including rheumatoid factor (RF), anti-citrullinated protein antibody (ACPA), medication, and bone erosion identified by X-ray or ultrasound, were compared across PRS quartiles. PRS derived from 97,396 SNPs via LDpred2 had the highest AUC. Participants in the highest quartile of RA-PRS had the highest proportions of rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA) positivity (74.8% and 65.0%, respectively), bone erosion (86.4%), and use of bDMARDs or tsDMARDs (42.3%) compared to the other quartiles. PRS remained a significant predictor of bone erosion, particularly in patients under 60 years of age, even after adjusting for RF, ACPA, and treatment. PRS is associated with seropositivity, erosive bone disease, and need for advanced therapy among Taiwanese patients with RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.